Reaffirmed Guidance and CFO Exit Might Change The Case For Investing In Zimmer Biomet (ZBH)

Zimmer Biomet Holdings reported past first-quarter 2026 results with sales of US$2,086.7 million and net income of US$238.1 million, reaffirming its full-year revenue guidance.Alongside continued share repurchases, the company announced the departure of its CFO and appointed its Controller and Chief Accounting Officer as interim CFO, raising questions about leadership continuity in its finance function.Next, we’ll examine how reaffirmed guidance alongside the CFO transition may influence...

Zimmer Biomet Holdings, Inc. (ZBH) Q1 2026 Earnings Call Transcript

Zimmer Biomet - Nachzieheffekte sorgen für starke Aussichten!

Geschäftstreiber: Zimmer Biomet (ZMB) ist vor allem bei Knie- und Hüftimplantaten sowie bei im S.E.T-Segment (Surgical, Sports Medicine, Foot and Ankle, Extremities und Trauma) stark aufgestellt und...

Zimmer Biomet Holdings, Inc. (ZBH) Q4 2025 Earnings Call Transcript

Zimmer cuts 2025 organic sales growth forecast on weakness in international markets

Zimmer Biomet Holdings cut its 2025 organic revenue growth forecast following weakness in Latin America and emerging markets in Europe that offset the companys strong performance in the U.S., sending shares 8.4% lower in premarket trading.

Zimmer Biomet raises annual profit forecast on strong demand for medical devices

Zimmer Biomet Holdings raised its full-year adjusted profit forecast and beat second-quarter earnings expectations on Thursday, bolstered by accelerating demand for its hip and knee implants.

Getinge and Zimmer Biomet announce strategic partnership in the ASC sector

GOTHENBURG, SWEDEN AND WARSAW, IND. – July 10, 2025 – Global MedTech companies Getinge and Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), today announced a strategic partnership where Zimmer Biomet will distribute Getinge’s Operating Room (OR) capital products to its Ambulatory Surgery Center (ASC) customers. This partnership creates a turnkey solution for ASC customers, who can now access Getinge’s infection control and surgical portfolio and Zimmer Biomet’s broad menu of best-in-class impla...

Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript

Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty

Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28 , currency volatility, and proposed tariffs.

Zimmer Biomet forecasts 2025 profit below estimates

Medical device maker Zimmer Biomet Holdings forecast full-year adjusted profit below Wall Street estimates on Thursday, as it anticipates a hit from a strong dollar.

Zimmer Biomet Aktie: Truist sieht Potenzial in stabiler Medizintechnikbranche

Charlotte, NC (www.aktiencheck.de) - Zimmer Biomet-Aktienanalyse von Truist: Rating und Kursziel Die Analysten von Truist haben das Kursziel für die Aktie von Zimmer Biomet Holdings Inc. (ISIN: US98956P1021, WKN: 753718, Ticker-Symbol: ZIM, NYSE-Symbol: ZBH) leicht von 117 USD auf 118 USD angehoben und ihre Einstufung "hold" beibehalten. [mehr]

Zimmer Biomet Aktie: Neue Produkte sollen Wachstumspotenzial stärken

New York (www.aktiencheck.de) - Zimmer Biomet-Aktienanalyse von J.P. Morgan Securities: 1. Überblick der Analyse JPMorgan hat die Aktie von Zimmer Biomet Holdings Inc. (ISIN: US98956P1021, WKN: 753718, Ticker-Symbol: ZIM, NYSE-Symbol: ZBH) von "neutral" auf "overweight" hochgestuft und das Kursziel von 125 USD auf 128 USD angehoben. [mehr]

Zimmer Biomet Aktie: Kursziel herabgesetzt

London (www.aktiencheck.de) - Rating-Update: Matt Miksic, Analyst von Barclays, stuft die Aktie von Zimmer Biomet Holdings Inc. (ISIN: US98956P1021, WKN: 753718, Ticker-Symbol: ZIM, NYSE-Symbol: ZBH) weiterhin mit "underweight" ein und senkt sein Ziel von 125 auf 118 USD. (Update vom 12.12.2024) Bitte beachten Sie auch Informationen zur Offenlegungspflicht bei Interessenskonflikten im Sinne der Richtlinie 2014/57/EU und entsprechender Verordnungen der EU für das genannte Analysten-Haus unter f...

Global Musculoskeletal Market Size is Expected To Hold a Significant Share By 2033 | CAGR of 6.2%

The Market Size is Growing at a Substantial CAGR of 6.2% from 2023 to 2033 and the Worldwide Musculoskeletal Market Size is Expected to Hold a Significant Share by 2033, according to a research report published by Spherical Insights & Consulting. Companies Covered: Zimmer Biomet Holdings, Inc., Stryker Corporation, Medtronic, Sanofi S.A, Bristol-Myers Squibb, Eli Lilly And Company, Mitsubishi Tanabe Pharma Corporation, EverEx, Horizon Therapeutics plc, Procter & Gamble, Eisai Co. Ltd. And Other ...

Global Biomaterials Market Size To Exceed USD 528.5 Billion By 2033 | CAGR of 13.77%

The Global Biomaterials Market Size was Valued at USD 145.5 Billion in 2023 and the Worldwide Biomaterials Market Size is Expected to Reach USD 528.5 Billion by 2033, according to a research report published by Spherical Insights & Consulting Companies covered: Berkeley Advanced Biomaterials, Carpenter Technology Corporation, Covalon Technologies Ltd., Stryker Corporation, Evonik Industries, Johnson & Johnson, Corbion, Medtronic, Zimmer Biomet Holdings, Inc., Invibio Ltd., Dentsply Sirona, Coors...

Zimmer Biomet Holdings: Moving Along

Zimmer Biomet Holdings, Inc. (ZBH) Q1 2024 Earnings Call Transcript

Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices

Medtech firm Zimmer Biomet Holdings beat Wall Street estimates for first-quarter profit on Thursday, on the back of robust demand for its devices that are used in knee and hip reconstruction procedures.